LOSS PER SHARE A computation of weighted average shares of common stock outstanding and loss per share for 2017, 2016 and 2015 follows: | | | | | | | | | | | | | | | | Year Ended December 31, | ($ amounts in millions, except per share amounts) | | 2017 | | 2016 | | 2015 | Net loss attributable to common stockholders | | $ | (296.2 | ) | | $ | (40.8 | ) | | $ | (308.6 | ) | Numerator adjustments for diluted loss per share: | | | | | | | Gain on settlement agreement related to Series B Convertible Preferred Stock | | — |
| | (103.0 | ) | | — |
| Gain on amendment of Series B Convertible Preferred Stock | | — |
| | (32.9 | ) | | — |
| Remeasurement adjustment associated with the Preferred Series B redemption liability | | — |
| | 5.0 |
| | — |
| Loss allocated to PDH non-controlling interest | | — |
| | (5.9 | ) | | — |
| Net loss attributable to common stockholders for diluted loss per share | | $ | (296.2 | ) | | $ | (177.6 | ) | | $ | (308.6 | ) | | | | | | | | Basic weighted average common stock outstanding | | 286.1 |
| | 243.3 |
| | 203.2 |
| Denominator adjustments for diluted loss per share: | | | | | | | Conversion related to the amendment of the Series B Convertible Preferred Stock - assumed at beginning of reporting period | | — |
| | 15.3 |
| | — |
| Settlement of preferred stock redemption liability - assumed at beginning of reporting period | | — |
| | 5.7 |
| | — |
| Conversion of PDH non-controlling interest | | — |
| | 8.0 |
| | — |
| Share adjustments | | — |
| | 29.0 |
| | — |
| Dilutive weighted average common stock outstanding | | 286.1 |
| | 272.3 |
| | 203.2 |
| | | | | | | | Loss per share attributable to common stockholders: | | |
| | |
| | |
| Basic | | $ | (1.04 | ) | | $ | (0.17 | ) | | $ | (1.52 | ) | Diluted | | $ | (1.04 | ) | | $ | (0.65 | ) | | $ | (1.52 | ) | | | | | | | | Dividends per share paid to common stockholders | | $ | — |
| | $ | — |
| | $ | — |
|
For 2017, 2016 and 2015, the following securities were not included in the computation of diluted shares outstanding because the effect would be anti-dilutive, or because performance targets and/or market conditions were not yet met for awards contingent upon such measures: | | | | | | | | | | | | | Year Ended December 31, | (amounts in thousands) | | 2017 | | 2016 | | 2015 | Shares issuable for the contingent consideration | | 7,421 |
| | 8,553 |
| | 4,640 |
| Shares issuable upon conversion of PDH Common Stock | | 5,967 |
| | — |
| | 8,318 |
| Shares issuable upon conversion of Series A Preferred Stock | | 2,000 |
| | 2,000 |
| | 2,000 |
| Shares issuable upon vesting of RSUs | | 842 |
| | 147 |
| | 74 |
| Shares issuable upon vesting and exercise of stock options | | 51 |
| | — |
| | 55 |
| Shares issuable under the ESPP | | 3 |
| | 2 |
| | 1 |
| Shares issuable upon conversion of Series B Convertible Preferred Stock | | — |
| | — |
| | 19,443 |
| Shares contingently issuable to Founder Entities as stock dividend to Series A Preferred Stock | | — |
| | — |
| | 1,239 |
| Total shares excluded | | 16,284 |
| | 10,702 |
| | 35,770 |
|
|